InNexus Biotechnology awarded federal grant

November 5, 2010

By Flinn Foundation

[Source: Finacial Times] – InNexus Biotechnology Inc., a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company’s development of DXL™ anti-cancer antibodies.

For more information: InNexus Biotechnology Awarded Federal Grant